

Cipla ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Emerging Markets Index

Mumbai, India; November 15, 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") announced today that it has been selected in the S&P Dow Jones Sustainability Index (DJSI) for the Emerging Markets for 2021. The DJSI family of indices is operated by one of the world's leading index providers S&P Dow Jones. The Emerging Markets Index for the year comprises of 108 companies from 12 emerging economies, including China, Brazil, South Africa and Taiwan.

Created jointly by S&P Dow Jones Indices and SAM, the DJSI is the gold standard for corporate sustainability, and is highly regarded by global investors and financial analysts looking at ESG-based investments. The DJSI follows a best-in-class approach, assessing sustainability leaders from each sector on a global and regional level. The selection process included the world's largest ~4000 listed companies, which underwent a rigorous assessment on Economic & Governance, Social & Environmental parameters such as corporate governance, ethics, risk management, climate change mitigation, stakeholder engagement, access to medicine, quality, corporate social responsibility and human resource practices.

As of November 12, 2021, Cipla performed in the top decile in the pharmaceutical Industry in the S&P Global Corporate Sustainability Assessment, with a ranking of 93 percentile in the industry, meaning 93% of companies reached an equal or lower ESG Score. The Company significantly improved performance in parameters like strategy to improve access to drugs or products, human capital development, tax strategy and climate strategy compared to last year.

Commenting on the ranking, Mr. Umang Vohra (MD and Global CEO, Cipla Limited) said, "The selection into S&P Dow Jones Sustainability Index Emerging Markets is a testament to our commitment towards sustainability, which is at the core of our DNA. We are delighted to be recognized for our efforts in climate action and social impact, coupled with strong corporate governance. This recognition strengthens our belief in investing in greener technology and processes, creating social impact for communities and serving the markets to create for healthier people and a healthier planet. We remain committed to building ecosystems for accessible and patient centric quality healthcare, underpinned by industry leading practices."

With the aim of reaching non-fossil fuel share of 40% by 2030, in January 2021, Cipla became the first pharmaceutical company in Maharashtra to invest in group captive open access solar power project of 30 MW capacity, spread across 115 acres. This has contributed to Cipla's decarbonizing goals, with the company now sourcing ~25% of its energy from renewable sources in the current year. Additionally, Cipla is also a constituent of the MSCI All Country World Index (ACWI) and has an ESG Rating of BB; as well as a constituent of FTSE4Good Index Series for the three consecutive years.

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA September 2021), 3rd largest in the pharma private market in South Africa (IQVIA MAT September 2021), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

For queries, please contact**Corporate Communications**

Heena Kanal

E-Mail: CorpComm@cipla.com